Vanguard Group Increases Stake in Krystal Biotech

Vanguard Group's Bold Move on Krystal Biotech Amplifies Market Impact

In a significant stock market maneuver, Vanguard Group Inc. has escalated its investment in Krystal Biotech, Inc. (NASDAQ:KRYS), amplifying its stake by an impressive 40.7% during the third quarter. This strategic acquisition has positioned Vanguard with a substantial 2,400,142 shares, commanding an 8.51% ownership in the biotech firm. The value of Vanguard's investment portfolio in Krystal Biotech soared to approximately $278,416,000, underscoring the biotech sector's burgeoning appeal among institutional investors.